Heart Failure

Shock-Phenotype Matching Using Real-World Evidence: A New Paradigm for Prospective Enrollment in Clinical Trials of Acute MCS Devices in Cardiogenic Shock

19 min.

A Novel Study Design, Termed Molecular Triangulation, That Leverages Biologic Similarities Across Seemingly Different Shock Phenotypes In Order to Identify Novel Druggable Targets and Pathophysiologic Mechanisms.

11 min.

DPP3-Based Biotherapy in Cardiogenic Shock

12 min.

Pulsatile ECMO

14 min.

Ivabridine in Cardiogenic Shock

13 min.

The Conundrum of Clinical Trials in Cardiogenic Shock

4 min.

Cardiogenic Shock: The Urgent Need for Innovation in Devices and Technologies for Shock

8 min.

Potential Benefits of Decreasing HR: Adjuntive Therapies to Pumps

8 min.

Istraoxime for Cardiogenic Shock

8 min.

The Impella Portfolio of Devices for Cardiogenic Shock (Left-Sided Support)

7 min.

Early Experience With the Supira Microaxial Flow Pump

6 min.

Early Experience With the Magenta Elevate™ Micro-Axial Flow Pump

5 min.

Innovations for RV Support in Shock

6 min.

Innovations in Management of ECMO-Supported Patients

17 min.

Risk Stratification: Thinking Beyond SCAI Staging

8 min.

Deep Phenotyping in Cardiogenic Shock

8 min.

Inotropes and Mortality in Patients With Cardiogenic Shock Due to Myocardial Infarction: Insights from the SWEDEHEART Registry

8 min.

DoReMe: Are Inotropes Helpful or Harmful?

8 min.

ECMO-Unload: Is This the Answer to ECLS-SHOCK?

8 min.

Pulmonary Artery Catheter in Shock (PACCS)

8 min.

The RECOVER IV Study Overview

15 min.

Clinical Trials for Cardiogenic Shock: Going Forwards, Backwards, or Sideways?

10 min.

Cardiogenic Shock in Stress Induced Cardiomyopathy Complicated by Left Ventricular Outflow Obstruction: Hemodynamic-Tailored Management

11 min.

IV Diltiazem Use in Patients with Atrial Fibrillation and Systolic Dysfunction

10 min.

Estimating the Effect of Mechanical Circulatory Support on Mortality, Complications, and Readmission Rates in Patients Admitted with ST-Elevation Myocardial Infarction with Cardiogenic Shock who underwent Percutaneous Coronary Intervention

10 min.

Initial Experience of ECMO and E-CPR in Cardiogenic Shock in a Tertiary Center in Mexico

9 min.

MCS in Cardiogenic Shock: Use It Selectively

15 min.

We Need Shock and Arrest Centers (Pro)

5 min.

Take Care of the Patient as Close to Home as Possible

5 min.

MCS in Cardiogenic Shock: Use It Routinely

5 min.

Con: Cardiogenic Shock Therapy Need Not Be Guided by Pulmonary Artery Catheter

9 min.

Pro: Cardiogenic Shock Therapy Must Be Guided by Pulmonary Artery Catheter

6 min.

State-of-the-art Lecture on Evidence for MCS in Cardiogenic Shock

11 min.

RV Support: When and How?

12 min.

When to Perform Venting in VA-ECMO

11 min.

Optimal Antithrombotic Strategies in MCS Use

10 min.

MCS in Shock: Access Site Selection and Prevention of Access Site Complications

14 min.

MCS in Shock: Choosing the Right Device Based on Hemodynamic Criteria

10 min.

The Conundrum of Clinical Trials in Cardiogenic Shock

16 min.

Con: Favorable Data Is Lacking on MCS in AMI Cardiogenic Shock (Randomized Data Are Needed)

17 min.

Pro: Most Patients With AMI Cardiogenic Shock Should Get MCS (Randomization Is Unethical)

6 min.

Con: VA-ECMO is not the Option of Choice for Cardiogenic Shock

14 min.

Con: Percutaneous LVADs are not the First Line MCS device of choice for Acute MI & Cardiogenic Shock

15 min.

Pro: VA-ECMO is the Option of Choice for Cardiogenic Shock

5 min.

Pro: Percutaneous LVADs are the First Line MCS device of choice for Acute MI & Cardiogenic Shock

6 min.

Con: The IABP is not a First-line MCS for Non-AMI Cardiogenic Shock

14 min.

Pro: The IABP is the First-line MCS for Non-AMI Cardiogenic Shock

5 min.

Coronary Keynote Lecture: When and How to Choose IABP, Impella, TandemHeart, or ECMO in CS

8 min.

Staged Strategic Treatment Pathway During Unique Biventricular Failure Case

10 min.

Tinkering the Ticker: TandemHeart to TAVR

10 min.

Safety and Efficacy of Istaroxime 1.0 and 1.5 µg/kg/min for Patients With Pre Cardiogenic Shock

12 min.

Assessing RV Function in Cardiogenic Shock: When to Pull the Trigger on MCS

8 min.

Role of Temporary MCS in Pulmonary Arterial Hypertension

9 min.

Cardiogenic Shock: ECMO Supported TAVR

12 min.

Cardiogenic Shock With MCS and Review of Shock Algorithm

6 min.

Aortic Stenosis With Acute LV Unloading With Septostomy

13 min.

Acute MR With MCS/TEER

6 min.

Influence of Body Surface Area, and Ventricular Dimensions on Impella 5.5 Outcomes

9 min.

Pulmonary Artery Catheter Use in Patients with Heart Failure Cardiogenic Shock (HF-CS): An Analysis from the Cardiogenic Shock Working Group (CSWG)

9 min.

Application of Exception from Informed Consent to a Multicenter Cardiogenic Shock Trial

9 min.

How Tightly Should Treatment Algorithms Be Prescribed in a Clinical Trial on Cardiogenic Shock? What Are The Key Treatment Protocol Elements?

9 min.

How Narrow or Broad Should Enrollment Criteria Be in Trials on Cardiogenic Shock to Achieve Clinically Interpretable Results?

7 min.

Hot Topics on Regulatory Issues in Caridiogenic Shock - FDA Perspective

8 min.

Biomarkers and Risk Stratification for Cardiogenic Shock

7 min.

Cardiogenic Shock: Patient Phenotyping and Prognostication

7 min.

Cardiogenic Shock: Customized Therapeutic Approaches in 2023

8 min.

Impella for Cardiogenic Shock: High Expectations From Ongoing Studies

9 min.

Should All ECMO Patients Receive LV Unloading (Include HYPO-ECMO)?

10 min.

SSO2 for AMI Shock: The ISO-Shock Trial (AMI)

7 min.

SEISMiC Trial: Isatroxime (lusi-inotrope) (HF shock)

6 min.

When To Transition From Medical to Device-Based Therapy

8 min.

What Do We Really Know About ECMO in Cardiogenic Shock?

8 min.

Trans-Valvular LV Support: a Glimpse Into the Future

9 min.

Intra-Aortic Balloon Counterpulsation: "I'll Be Back"

7 min.

Treating the Right Ventricle in Cardiogenic Shock: the Next Frontier in Improving Outcomes

7 min.

How SCAI Classification Has Revolutionized Approach to Cardiogenic Shock

7 min.

Artificial Intelligence Will Revolutionize Risk Stratification and Guide Therapy for Cardiogenic Shock

7 min.

LVAD Associated Aortic Regurgitation: Treatment With a Dedicated TAVR System

11 min.

TCT 611: Amniotic Fluid Embolism-Induced Cardiopulmonary Collapse Successfully Treated with Combination VA-ECMO and Impella CP

6 min.

TCT 688: An Unfortuante Trifecta: A case of  acute myocardial infarction with cardiogenic shock, pericardial tamponade, and worsening hypoxia with right to left shunt after percutaneous LVAD placement.

6 min.

TCT 640: POST MYOCARDIAL INFARCTION VENTRICULAR SEPTAL RUPTURE WITH HEART FAILURE AND CARDIOGENIC SHOCK : CHALLENGES AND DEVICE CLOSURE

6 min.

TCT 808: Cardiogenic Shock and Severe MR treated with NTW MitraClip: Bridge to stabilization - GDMT

5 min.

TCT 774: Transcatheter Edge-to-Edge Repair in Primary Severe Mitral Regurgitation Complicated by Cardiogenic Shock 

5 min.

TCT 638: Sequential transcatheter treatment of severe mitral and aortic regurgitation with MitraClip and JenaValve Trilogy in a patient with cardiogenic shock

5 min.

Cardiogenic Shock Trials: Defining the Clinical Need and Framing the Issues

10 min.

Is There a Role for MCS in Massive PE and Which Modality?

8 min.

Assembling the Safest Solution for Hemodynamic Support in Heart Failure (Puzzle Medical)

8 min.